Cost-Effectiveness of the Optical Imaging Agent Hexaminolevulinate for Patients with Non-Muscle Invasive Bladder Cancer

Marteau, Florence; Kornowski, Anne; Bennison, C.; Tempest, Michael; Mariappan, Paramananthan; Witjes, J. Alfred

doi:10.1016/j.jval.2013.08.493

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Une étude allemande a montré que la réalisation d'une technique de diagnostic photodynamique des tumeurs de vessie non invasives était associée à des économies pour le système de santé allemand [19]. Le modèle qui a été utilisé dans cette étude a aussi permis de montrer que l'utilisation d'Hexvix ® est associée à la réalisation d'économie au Royaume-Uni [20], en Italie et en Allemagne.…”

Section: Discussionunclassified

Coût–efficacité de la résection transurétrale de vessie en lumière bleue chez les patients atteints d’un cancer de la vessie non infiltrant en France

Rouprêt

Malavaud²,

Molinier

et al. 2015

Progrès en Urologie

Self Cite

View full text Add to dashboard Cite

Section: Discussionunclassified

Coût–efficacité de la résection transurétrale de vessie en lumière bleue chez les patients atteints d’un cancer de la vessie non infiltrant en France

Rouprêt

Malavaud²,

Molinier

et al. 2015

Progrès en Urologie

Self Cite

View full text Add to dashboard Cite

“…85,86 In addition, three budget impact models (BIMs) and eighteen CEAs were identified from SLR searches, of which twelve evaluated TURBT, mainly comparing diagnostic imaging during the procedure as well as comparing TURBT to other procedures or procedure setting. [87][88][89][90][91][92][93][94][95][96][97][98] Two studies assessed intravesical therapy; 99,100 four assessed surveillance. [101][102][103][104] Four studies evaluated BCG and/or the impact of its shortage, [105][106][107][108] with one being a CEA that presented AE costs associated with BCG in high-risk patients.…”

Section: Economic Outcomesmentioning

confidence: 99%

<p>Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews</p>

Lee¹,

Kwon²,

Forsythe³

et al. 2020

CEOR

View full text Add to dashboard Cite

Purpose: Non-muscle invasive bladder cancer (NMIBC) is a malignancy restricted to the inner lining of the bladder. Intravesical Bacillus Calmette-Guerin (BCG) following transurethral resection of the bladder tumor is the mainstay first-line treatment for high-risk NMIBC patients. Two systematic literature reviews (SLRs) were conducted to further assess the current evidence on BCG use in NMIBC and the humanistic and economic burden of disease. Methods: Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, Embase ® and MEDLINE ® were searched using the Ovid platform to identify interventional or real-world evidence studies on the health-related quality of life (HRQoL) and economic burden in NMIBC. Limited evidence was found from initial economic SLR searches in NMIBC, so additional targeted searches for bladder cancer were conducted to expand findings. Results: Fifty-nine publications were included in the HRQoL SLR, of which 23 reported HRQoL and symptoms in NMIBC. At diagnosis, HRQoL was comparable with population norms but worsened considerably 2 years following diagnosis. Maintenance therapy with intravesical BCG was associated with reduced HRQoL, and treatment-related adverse events (AEs) resembled typical NMIBC symptoms. Twenty-two studies reported decreasing BCG compliance over time. Common AEs with BCG were frequent urination, lower urinary tract symptoms, pain, and hematuria. Forty-two publications were included in the economic SLR, of which nine assessed healthcare costs and resource use in NMIBC or bladder cancer. Highrisk disease and high-intensity treatment were associated with increased healthcare costs. Conclusion: NMIBC has a considerable symptomatic, HRQoL, and economic burden. Symptoms persisted and HRQoL worsened despite intravesical BCG treatment. NMIBC is a costly disease, with higher healthcare costs associated with increased risk of disease progression and recurrence. There is a high unmet need for safe and effective treatments that reduce the risk of disease progression and recurrence, provide symptomatic relief, and improve HRQoL for patients.

show abstract

Hexaminolevulinate: a profile of its use with blue-light cystoscopy in the diagnosis of bladder cancer

Lyseng‐Williamson¹

2017

Drugs Ther Perspect

View full text Add to dashboard Cite

Cost-Effectiveness of the Optical Imaging Agent Hexaminolevulinate for Patients with Non-Muscle Invasive Bladder Cancer

Cited by 3 publications

References 0 publications

Coût–efficacité de la résection transurétrale de vessie en lumière bleue chez les patients atteints d’un cancer de la vessie non infiltrant en France

Coût–efficacité de la résection transurétrale de vessie en lumière bleue chez les patients atteints d’un cancer de la vessie non infiltrant en France

<p>Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews</p>

Hexaminolevulinate: a profile of its use with blue-light cystoscopy in the diagnosis of bladder cancer

Contact Info

Product

Resources

About